RACGAP1 and MKI67 are potential prognostic biomarker in hepatocellular carcinoma caused by HBV/HCV via lactylation

Abstract

Introduction:

Hepatocellular carcinoma (HCC) is recognized as the prime and lethal form of liver cancer caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV) globally. Lactate is an end product of glycolysis that influences epigenetic expression through histone lactylation. While MKI67 and RACGAP1 play crucial roles in HBV- and HCV-related HCC. However, the role of lactylation-related genes (LRGs) effects in this context remains unclear. This study innovatively explored the role of LRGs in HBV/HCV-associated HCC, identifying novel biomarkers for diagnosis and prognosis.

Methods:

The present study used various online databases for analysis, and the findings were validated via immunohistochemical (IHC) analysis of HCC patient samples (n=60).

Results:

We identified six signature LRGs (ALB, G6PD, HMGA1, MKI67, RACGAP1, and RFC4) possess prognostic potential, correlation with immune infiltration, and lactylation-related pathways, providing novel insights into tumor microenvironment (TME) of HCC. Moreover, MKI67 and RACGAP1 were significantly associated with HBV- and HCV-related HCC. IHC confirmed these findings, with high expression of MKI67 and RACGAP1 was significantly linked with HBV/HCV-associated HCC compared to non-viral HCC. The expression is also significantly associated with key clinical variables.

Conclusion:

Our results suggest that MKI67 and RACGAP1 could serve as promising biomarkers for detecting and predicting HCC caused by HBV/HCV via lactylation, opening a new direction for immune-targeted therapies.

Introduction

Hepatocellular carcinoma (HCC) is the most common lethal form of liver cancer worldwide, accounting for 80% of liver cancers, and is the third leading cause of cancer-related deaths (1, 2). HCC typically affects individuals aged 30–50 years and is associated with various risk factors, such as hepatitis B or hepatitis C, alcohol abuse, smoking, obesity, and type 2 diabetes (1, 3). Notably, 80% of liver cancers are linked to viral infections (4). Despite multiple treatment options for HCC, such as surgery, transplantation, radiation, and chemotherapy, the 5-year survival rate is less than 20% (5). Therefore, it is crucial to find new biomarkers to support in diagnosis, improve survival, and monitor the reoccurrence of liver cancer. Investigating genes for HBV/HCV-related HCC via lactylation could enhance our understanding of the virus’s contribution to HCC development and potential therapeutic targets.

While the ability of HBV and HCV to affect liver cancer is well documented (6), the precise mechanisms by which these viruses contribute to HCC progression remain unclear. HBV infection leads to numerous health problems and fatalities associated with liver diseases such as HCC, cirrhosis, and liver decompensation (7). Recent estimates revealed that one in three liver cancer deaths are linked to HBV (8, 9). Chronic HBV infection is a prominent cause of death from liver cirrhosis and HCC, with approximately 0.82 million deaths annually (10). Despite widespread HBV vaccination, approximately 296 million cases were reported in 2019, and 1.5 million new infections are reported each year (11).

Numerous studies have shown that HCV infects approximately 17 million people annually, with approximately 71 million infections to date (12). If HCV is left untreated, it can lead to chronic viral infection, and approximately 20% of these patients develop liver cirrhosis. Once cirrhosis develops, 1–4% of patients progress to develop liver cancer each year (13). Additionally, 33% of people with HCV who do not have cirrhosis will also develop liver cancer within 30 years (14).

It is commonly believed that eradicating a viral infection can prevent the progression of virus-related cancer. Direct antiviral agents (DAAs) eliminate HCV, but liver cancer can still develop in individuals with advanced liver diseases. Recent research revealed an increase in liver cancer rates even after successful HCV eradication with DAAs (15). These findings reveal that removing the virus and infection treatment are insufficient to halt liver cancer development. To effectively understand and prevent cancer caused by viruses, it is crucial to study how viruses affect cellular processes, including cell growth, movement, and genetic changes (16). Identifying signature genes for HBV/HCV could provide a means for the early diagnosis and management of HCC.

Employing gene signatures at the mRNA level enhances the prognosis of individuals with HCC. Previous studies have demonstrated that gene signatures can predict liver cancer development (17, 18). Lactylation, a new approach to protein modification discovered in 2019, involves the addition of lactate molecules to lysine residues (19). The Warburg effect is characterized by increased anaerobic glycolysis and the production of lactic acid (20, 21). For example, researchers have reported that in liver cancer, the less efficient sugar-processing enzyme HK4 is replaced by the more efficient HK2, leading to increased glucose uptake by cancer cells (22). A 2023 study revealed that KIF2C (Kinesin Family Member 2C) is linked to MKI67, RACGAP1, RFC4, and STMN1 at the transcriptome level, suggesting that these genes might play a role in lactylation-related processes in HCC (23). This research also revealed that LRGs could be used to diagnose and treat HCC (23). Although researchers have identified the importance of specific genes in HCC (17, 24, 25), further studies are needed to explore the significance of LRGs, especially in HBV/HCV-induced HCC.

The impact of MKI67 and RACGAP1 on HCC linked to hepatitis B and C is a vital subject for research. MKI67 is a recognized marker used to detect cellular proliferation (26, 27). It has been associated with genetic changes near the TTN and CCDC8 genes in HBV-related liver cancer (28). These changes could be useful for predicting patient outcomes. The overexpression of MKI67 is linked to worse overall survival (OS) and increased reoccurrence rates in patients with HBV-related liver cancer (28). Recent studies have also revealed a connection between MKI67 and HCV-related liver cancer. Certain microRNAs in naive T cells are connected to MKI67 expression, suggesting that MKI67 may play a part in liver cancer related to both HBV and HCV (29).

RACGAP1 plays a pivotal role in cell division and cell cycle regulation. Recent studies have demonstrated that RACGAP1 is a valuable marker for predicting outcomes and understanding the immune response in various cancers, including liver cancer (30). The overexpression of RACGAP1 has been linked with poor prognosis and enhanced metastasis in multiple cancers, including HCC (31). For example, a 2015 study reported increasing the aggressiveness of tumors and facilitating lymph node metastasis in patients with colorectal cancer (32). Similarly, a study focusing on HCC revealed that RACGAP1 interacts with HIF-1alpha, influencing hepatocarcinogenesis (33). These findings emphasize the multidirectional role of RACGAP1 in cancer development and highlight its role as a therapeutic target.

Furthermore, recent studies have also underscored the role of lactylation, a novel epigenetic modification, in cancer progression. LRGs influence cancer biology, including immune infiltration and prognosis, in various cancer types (21, 34). For example, a multiomic study identified RACGAP1 as one of the hub LRGs associated with poor prognosis and immune infiltration (21). Similarly, metabolic reprogramming is frequently observed involving alteration of fatty acid synthesis, glucose metabolism, and overall metabolic process in HCC (21). These studies suggest that lactylation could play a crucial role in modulating cancer progression.

This study identified a set of LRGs for HCC by using “The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC)”, three “Gene Expression Omnibus (GEO)” datasets, and a previously published LRG list. We employed various bioinformatic tools to identify virus-related genes, which were validated via IHC analysis of human liver tissue samples. Furthermore, we investigated the relationships among the TME, immune infiltration, gene expression, and clinical variables. This study aimed to identify potential signature genes for HCC caused by HBV/HCV for screening and management. Our results indicate that MKI67 and RACGAP1 are significantly associated with immune infiltration and prognosis in HCC, suggesting their role as biomarkers for early diagnosis and targeted treatments.

Materials and methods

Data collection and identification of DEGs related to HCC

The mRNA transcriptome profiles and corresponding clinical information of 377 patients were downloaded from the TCGA database (https://protal.gdc.cancer.gov/) (34, 35). A scale method-based normalization approach was performed with the gene expression profiles via the R package “limma” (v3.60.4). This method was chosen because of its wide use in medical research, its robustness in handling RNA-seq data, and its ability to ensure that the normalized data are suitable for downstream analysis. The expression profiles of genes related to HCC were obtained from the GEO (36). Three GEO datasets, GSE14520 (37), GSE114564 (38), and GSE25097 (39) were selected to identify DEGs via GEO2R between HCC and nontumor samples (40). The cutoff for DEGs was set as |log2FC| > 1 and adjusted p-value < 0.05. These thresholds were chosen to ensure that the identified DEGs comprised a significant and biologically relevant change in expression levels.

To identify similar genes across all four datasets, the “VennDiagram” R package was used. This package was selected to facilitate the identification of genes that are common in different datasets (41).

Expression, PPI, and functional enrichment analysis of DEGs

Volcano plots were created to visualize the relationships among the common DEGs via the “ggplo2” R package (42), with significance thresholds of p values <0.05 and |log2FC| >1. We constructed a protein-protein interaction (PPI) network and heatmap via the ‘igraph’ and ‘pheatmap’ R packages, respectively (43, 44). The PPI network was generated based on STRING-backed data, and a heatmap was designed by using expression data of DEGs across the datasets. For functional enrichment analysis, the “enrichplot” R package was employed for GO and KEGG pathway analysis. This analysis investigated the potential biological functions of the DEGs (45).

Identification of lactylation-related DEGs via the LASSO model construction

Previously reported 330 LRGs were selected (23) to identify the LRGs from the common DEGs via the “VennDiagram” R package (41). This intersection helped us to identify genes common to both datasets. We employed the ‘ggplot2’ R package to visualize lactylation-related DEGs in volcano plots based on their expression (46). The PPI network was constructed via the ‘igraph’ package, with data retrieved from the STRING database (43). This network helped us visualize the linkages between proteins. Furthermore, the R package “enrichplot, clusterProfiler” was employed for Gene Ontology (GO) analysis to investigate the potential biological functions of lactylation-related DEGs (45). Finally, a correlation heatmap was created via the ‘pheatmap’ package between lactate accumulation genes and production-associated genes (LDHA, LDHB, EP300, and HIF1A) in the TME and LRGs (47). Moreover, to verify the prognostic significance of the LRGs in HCC, a predictive model was executed via least absolute shrinkage and selection operator (LASSO) regression via the “glment” R package. The risk score for each HCC patient was calculated (risk score = Σ (coefficient × gene expression)), where the coefficient and expression level (E) corresponded to each LRG. OS was compared between the high- and low-risk groups via Kaplan–Meier (KM) curves. Additionally, we conducted a correlation analysis between LRGs and widely recognized biomarkers (48).

Gene expression profiling and survival analysis for LRGs

We validated the expression patterns of the identified lactylation-related DEGs via The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN, http://ualcan.path.uab.edu/) (49) and the Gene Expression Profiling Interactive Analysis (GEPIA) web tool (http://gepia.cancer-pku.cn/ accessed on July 7, 2020) (50). These online tools provide comprehensive expression data across cancer types. Consequently, to assess overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS), we utilized KM plotter (https://kmplot.com/ accessed in October 2023) (51, 52). This tool allows us to perform real-time survival analysis between high- and low-risk groups.

Immune infiltration and pathway correlation analysis of the LRGs

Gene set cancer analysis (GSCA) was used to assess the correlation of methylation and pathways (inhibitors, activators) with the identified LRGs in liver cancer. This widely used platform has 7876 samples from 32 types of cancer, providing comprehensive cancer-related pathway analysis (53). Additionally, we investigated the correlation of LRGs with immune checkpoint inhibitors (ICIs). The R package “tidyverse” was used to prepare the data, and “ggplot2” was used to create a heatmap. Moreover, the TIMER tool was used to validate the relationships between the expression of six LRGs and immune cells across 40 cancer types from TCGA data (“https://cistrome.shinyapps.io/timer/) (51, 54) via the deconvolution method.

Drug sensitivity to LRG mRNA expression

In addition to immune cell correlation, we conducted drug-gene interaction analysis for six LRGs via the Drug–Gene Interaction Database (DGIdb), which was accessed on Dec 21, 2023 (55). These data have been widely used in previous studies and consolidate data from various sources to demonstrate drug-gene interactions and gene categories. Furthermore, the Genomic of Drug Sensitivity in Cancer (GDSC) database was utilized to determine the correlation between the identified LRGs and drug sensitivity. This widely used platform has an IC50 of 265 molecules in 860 cell lines (56).

Gene enrichment and virus interactions analysis

This study investigated six LRGs and oncoviruses associated with liver cancer via the OncoDB database (https://oncodb.org/, Accessed on Feb 12, 2024). A p-value>0.05 was considered to indicate statistical significance. Furthermore, gene set enrichment analysis (GSEA) was performed via the CAMOIP (www.camoip.net) web tool. This web tool facilitated the elucidation of the biological pathways and mechanisms associated with these genes.

Immunohistochemical staining

Our comprehensive bioinformatic analysis of the six LRGs revealed that MKI67 and RACGAP1 were significantly associated with HBV and HCV in HCC. We conducted an immunohistochemical study of the patient’s liver tissue to validate these findings. This study was conducted after approval from the Institutional Review Board of the First Affiliated Hospital of Dalian Medical University (Approval number: “PJ-KS-KY-2018-07 (X)”). Written informed consent was obtained from all participants. All methods were conducted in accordance with the Declaration of Helsinki. Liver tissue samples were collected from 60 individuals with HCC, including 20 individuals diagnosed with HCC without infection, 20 with HBV, and 20 with HCV infection. The etiological information for selected HCC samples without infection included 17 males and 03 females (n=20), while for HCC samples with HBV, 17 males and 03 females (n=20) were included, and for HCC samples with HCV, 16 males and 4 females (n=20) were included. Detailed clinical information on these patients is given in Table 1.

Immunohistochemical staining was conducted as described in previous studies (57, 58). Briefly, formalin-fixed, paraffin-embedded tissues were removed and mounted on glass slides. The sections were deparaffinized with xylene and rehydrated through a series of ethanol dilutions (100% to 70%). Antigen retrieval was performed via citrate buffer (pH 6.0) in a pressure cooker for 10 minutes with proper heating (90–95°C). Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in methanol for 30 minutes at room temperature.

The sections were then blocked with 3% BSA (Sigma–Aldrich, St. Louis, MO, USA) at room temperature for 30 minutes to prevent nonspecific binding. The sections were incubated with primary antibodies against MKI67 (1:100 dilution, Ki67 rabbit mAb (A20018) and RACGAP1 (1:100 dilution, RACGAP1 rabbit mAb (A24948), ABclonal) overnight at 4°C. After being washed with PBS, the sections were incubated with an HRP-labeled goat anti-rabbit IgG (1:200; GB23303; Servicebio) secondary antibody for 30 minutes at room temperature. The immunoreaction was visualized via 3,3’-diaminobenzidine (DAB) counterstaining with hematoxylin. The sections were washed, and the slices were dehydrated with alcohol and cleared in xylene. Images were captured via a light microscope (LEICA DM 2500) at 40x magnification. The expression levels of MKI67 and RACGAP1 were quantified via the optical density (OD) method by two independent scholars. Five random high-power fields (40×) were selected for each section, and the OD values were measured using ImageJ software (NIH, USA).

Statistical analysis

Statistical analyses were performed using R software (version 4.4.1). The normality of data distribution was assessed using the Shapiro–Wilk test and one-way Analysis of Variance (ANOVA) to compare OD values across different conditions for each gene. A p-value < 0.05 was considered statistically significant.

Results

Comprehensive analysis to identify differentially expressed genes associated with HCC

We identified DEGs from TCGA-LIHC and GEO datasets via the “limma” R package and the GEO2R analysis tool. The limit for DEGs was set at a log2-fold change (log2FC > 1) and a p-value < 0. 05). The TCGA-LIHC dataset identified 19840 DEGs; subsequently, the GEO datasets (GSE14520, GSE114564, and GSE25097) identified 1100, 3100, and 1872 DEGs, respectively (Supplementary File-S1). The volcano plots (Figures 1A-D) represent the gene expression variations in liver cancer, with red dots indicating upregulated genes, blue dots representing downregulated genes, and gray dots representing genes whose expression was not significantly altered. The x-axis shows the log2-fold change, and the y-axis shows the -log10(adjusted p-value). These visualization provide a summary of significant expression changes in dataset of HCC. Moreover, the “VennDiagram” R package was used to identify common genes, and we identified 244 common DEGs across all selected datasets (Figure 1E; Supplementary File-S2). Figure 1F shows a plot illustrating the interactions of the DEGs, which indicate the connection of LRGs. This PPI interaction indicate the functional relationships between DEGs in HCC. Finally, the heatmap (Figure 1G) visually compares gene expression across the datasets, with red indicating upregulated genes, blue indicating downregulated genes, and white indicating genes with minimal expression. This heatmap helps us compare how genes are expressed in different studies in HCC. These findings indicate that the identified DEGs might be crucial for identifying potential biomarkers of lactylation and targets for the treatment of HCC.

Figure 1

Functional enrichment and pathway analysis of DEGs associated with HCC

Our previous findings of Figure 1 explicated the relationships between common DEGs via PPI and differential expression. To further explore the significance of DEGs, GO and KEGG analyses were used to elucidate the role of DEGs in HCC progression and development. We selected the top ten significant GO terms and KEGG pathways (p values < 0.05). The DEGs were involved mainly in metabolic processes, including the xenobiotic metabolic process, the cellular response to xenobiotic stimulus, the olefinic compound metabolic process, and the steroid metabolic process (Figures 2A-C). These findings revealed the involvement of metabolic pathways in HCC development, which is relevant to lactylation process. Furthermore the KEGG analysis revealed that the DEGs are significantly involved in various metabolism-related pathways (Figure 2E), such as fatty acid degradation, drug metabolism, etc. In the bar and bubble plots, the x-axis shows the gene ratio, and the color indicates the adjusted p-value, whereas the y-axis is labeled with enrichment terms and KEGG pathways. The network plots (Figure 2D, F) depict node size as the gene count, edge thickness as the term overlap, and node color as the significance (darker = lower p-value). These analyses revealed key biological processes, cellular components, molecular functions, and pathways potentially involved in HCC development and progression, which is relevant to our study. Table 2 lists the top five GO terms, which include B.P., CC, and M.F. (Supplementary-S3). Collectively, these findings highlight the involvement of DEGs in metabolic processes, suggesting their importance for lactylation in HCC.

Figure 2

Identification and analysis of lactylation-related genes and the protein-protein interaction network associated with HCC

A comprehensive analysis was conducted to identify LRGs in HCC, integrating multiple analytical approaches. The “VennDiagram” R package was used to identify the genes common to the DEGs (244) and LRGs (330): ALB, G6PD, HMGA1, MKI67, RACGAP1, and RFC4 (Figure 3A). We visualized the expression of six LRGs through a volcano plot by using ‘ggplot2’ (Figure 3B), where red highlights indicate upregulated genes and blue highlights indicate downregulated genes. The results revealed that five genes were upregulated, whereas ALB was downregulated. Taken together, the PPI networks (Figure 3C) revealed intricate connections between lactylation genes and other proteins, particularly those involved in glycolysis, suggesting a potential link to altered metabolism in HCC. The analysis revealed that these six LRGs are closely related to several glycolysis-related proteins (e.g., PFKL, PKM, PGAM1, ALDOA, and GAPDH) and other LRGs (e.g., LADHA, LADHB, and LADHC). Literature analysis plots (Supplementary-S7-I) revealed that MKI67, RACGAP1, and RFC4 have limited publications, suggesting their potential innovation and distinctiveness in HCC therapy.

Figure 3

Functional enrichment and correlation analysis of the genes related to lactylation in HCC

We performed enrichment analysis on the six lactylation-related DEGs to explore their potential in the progression of HCC via R software. The results revealed that these genes were enriched mainly in cell cycle-related terms, including condensed chromosomes, the cytoplasmic side of the membrane, DNA conformation changes, and myeloid cell homeostasis (Figure 3D). These enrichments are known to be involved in the regulation of energy metabolism and have been implicated in cancer development. The correlation heatmap (Figure 3E) further illustrates the interrelationships between the identified lactylation-associated genes and genes associated with lactylation accumulation in HCC. Overall, this multifaceted analysis underscores the potential significance of lactylation-associated genes in HCC pathogenesis, particularly concerning the regulation of energy processes, and provides a foundation for future investigations into their roles in cancer development and potential therapeutic targeting.

Construction and validation of the prognostic model for HCC using TCGA-LIHC data

Furthermore, the LASSO model was employed to identify prognostic markers among the LRGs (Figure 3F). The results revealed that ALB had the lowest coefficient value, whereas RFC4 had the highest coefficient value, with the others also showing significant values. These findings suggest that these genes could potentially play a role in predicting patient prognosis. Subsequently, cross-validation for LASSO was represented by a lambda plot (Figure 3G). The KM plot revealed significant differences in OS between the high- and low-risk groups for MKI67 and RACGAP1, with a p-value <0.05 (Figure 3H). Additionally, a univariate Cox regression analysis (Figure 3I) confirmed the significance of all the LRGs except for ALB. Finally, the nomogram model results illustrated (Figure 3J) the predictive power of the identified LRGs. To further validate these findings, we compared our LRGs with five widely used biomarkers (GPC3, HSP70, GP73, OPN, and AFP) reported in recent studies (48). Our results revealed that MKI67 was significantly positively correlated with GPC3 and AFP, whereas RACGAP1 was significantly positively associated with OPN and GPC3. Both MKI67 and RACGAP1 were significantly negatively correlated with GP73 (Supplementary S6). Collectively, these results suggest that LRGs may serve as robust prognostic markers in HCC.

Validation of expression, stage-specific expression and survival analysis of LRGs in HCC

We conducted the expression analysis of six LRGs in both normal and primary tumor samples of HCC. ALB was significantly lower in primary tumors compared to normal samples (p <0.05). The expression levels of G6PD, HMGA1, MKI67, RACGAP1, and RFC4, were significantly higher in tumor samples with (p < 0.05) (Figures 4A, D, G, J, M, P). The blue violin plots represent the distribution the frequency of expression levels, across different HCC stages (Figures 4B, E, H, K, N, Q). F values and corresponding p values from ANOVA are provided in the plots. Moreover, we investigated the OS of LRGs with both low and high expression levels (Figures 4C, F, I, L, O, R). The log-rank p values were < 0.05, with hazard ratio (HR) values of 2.52 (1.77–3.59), 2.08 (1.47–2.95), 1.96 (1.38–2.77), 1.96 (1.38–2.77), and 1.81 (1.26–2.59), respectively. Thess findings revealed the differential expression of LRGs between normal and tumor tissues, various stages and their association with overall survival. These results underscoring the potential of LRGs as prognostic biomarker in HCC.

Figure 4

Similarly, we also investigated the PFS and recurrence-free survival (RFS) suggesting their involvement in HCC progression and development. High expression of G6PD, HMGA1, MKI67, RACGAP1 associated with these LRGs at both low and high expression levels (Supplementary-S4-A, B). These findings highlight their specific potential as markers for HCC diagnosis and prognosis.

Analysis of immune infiltration and pathways associated with LRGs in HCC

By using the web tool “GSCA”, we investigated immune infiltration and methylation with the expression of six LRGs in liver cancer. The results revealed a significant correlation between these LRGs and various immune cells, such as B cells, Tregs, DCs, macrophages, and myeloid dendritic cells, in liver cancer (Figure 5A). The dot plot shows a remarkable positive correlation with Tregs and B cells and a negative correlation with macrophages, monocytes, NK cells, etc. Red indicates a positive correlation with immune cells, whereas blue indicates a negative correlation, with significant stars. The heatmap depicted the mean correlation between methylation and immune infiltration of the six LRGs in liver cancer (Figure 5B), including a significant association. These results indicate that significant positive and negative correlations between these genes may indicate aberrant histone methylation activity, which could be crucial in cancer development.

Figure 5

To further elucidate the pathways involved, the findings highlighted that these LRGs are significantly correlated with cancer-related pathways, such as apoptosis, the cell cycle, and DNA damage (Figures 5C, D). Additionally, correlation analysis between the LRGs and ICI using TCGA-LIHC data (Figure 5E) indicated that the five genes were significantly positively correlated with ICI, whereas ALB was negatively correlated. Collectively, these findings suggest that the six LRGs could be potential biomarkers, highlighting their role in the TME, which could be important for developing targeted immunotherapy in HCC. Additional informative analysis of immune cells with LRGs via TIMER data is shown in Supplementary Figure S5.

Exploring drug-gene interactions of lactylation-related genes in HCC

Our results from gene-drug interactions revealed 163 drug interactions, with 81 drugs approved by the Food and Drug Administration (FDA) with three genes (RACGAP1, G6PD, and ALB) shown in Supplementary S6A. Further analysis revealed that 13 of these approved drugs are also related to immunotherapy. Moreover, the GDSC platform was used to determine the correlation between mRNA expression and drug sensitivity in cancer (Supplementary Figure S6B, C). The results indicated that most of the identified LRGs are negatively correlated with drug sensitivity, except G6PD. These findings emphasize the potential and clinical importance of the identified LRGs in HCC therapies.

Integrated expression profile with OncoDB and GSEA of lactylation-related genes in HCC

Furthermore, GSEA was conducted for MKI67 and RACGAP1 by dividing the gene profile into high-expression groups and low-expression groups. Box plots represent the 10 enriched processes, which are related mostly to the regulation of energy in cancer, such as the lactate metabolic process, KEGG glycolysis, and the cell cycle (TCA) (Figures 6A, B). The expression profile of six LRGs were analyzed via “OncoDB”. The results revealed significant correlations between MKI67 and RACGAP1 with both HCV-HCC (p < 0.05) and HBV-HCC (p > 0.05) (Figures 6C-F). Aditionally, RFC4 also demonstrated a robust correlation with HBV-HCC (p < 0.05).

Figure 6

Althogh the MKI67 and RACGAP1 were significantly differentially expressed between positive and negative HCV, but we observed the higher median of expression in HCV-negative compared to the HCV-positive patients. This discrepancy maybe due to the attributed disparity in sample sizes beween the groups. To validate these findings we conducted external validataion. The two HCV-related datasets (GSE140845, and GSE154211) were selected frome GEO database. The analysis employed between HCV-positive v.s HCV-negative HCC samples (Supplementary-S7, S8). The results confirmed that all the HCV-related HCC has high expression values of MKI67 and RACGAP1 as compared to non-viral samples.

These findings suggest that these genes may play critical roles in the progression of HBV/HCV-induced HCC. The other genes (G6PD, HMGA1, and ALB) presented weaker associations with HBV/HCV-induced HCC, indicating that their roles might be more general in HCC pathogenesis than specific to viral etiology (Supplementary-S8). These results collectively highlight the potential of LRGs as biomarkers and therapeutic targets in HCC, particularly in viral hepatitis-associated HCC. The identified drug interactions and differential expression patterns provide a foundation for further investigations into novel treatment strategies for HCC.

Immunohistochemical validation of MKI67 and RACGAP1

We collected HCC patient samples (n=60), including 20 from patients with HCC without the virus, 20 from patients with HBV-HCC, and 20 from patients with HCV-HCC. The results of the “ANOVA” revealed a significant effect of condition on the OD values of both genes. MKI67 p < 0.05, and RACGAP1, p < 0.05. Pairwise t-tests with Bonferroni correction for MKI67 indicated significant differences between HCC, HBV-HCC, and HCV-HCC patients (p < 0.05) (Figures 7A, C, E). For RACGAP1, significant differences were observed between HCC, HBV, and HCV (p < 0.05) (Figures 7B, D, F).

Figure 7

The Kruskal–Walli’s test confirmed the significant effects of condition on the OD values for both MKI67 (χ² (2) = 30.004, p < 0.05) and RACGAP1 (χ² (2) = 17.630, p < 0.05). Dunn’s test for MKI67 also revealed significant differences between HCC, HBV, and HCV (p = 0.05). For RACGAP1, a significant difference was found between HCC, HBV, and HCV (p < 0.05), whereas differences between HBV and HCV (p = 0.79) were not significant boxplots (Figure 7G). Our results revealed that patients diagnosed with HCV had much higher expression levels of MKI67 and RACGAP1 than did patients diagnosed with HBV or HCC. MKI67 levels varied across all groups, whereas significant differences in RACGAP1 were observed only between the HCV-HCC and HBV-HCV groups. There was a notable association between pathological grade and RACGAP1 (p=0.001), but for MKI67, it was not significant (p=0. 07). These findings highlight the differential expression of MKI67 and RACGAP1 in HCC, HBV, and HCV (Figure 7H) and provide valuable insights into the molecular mechanisms underlying these diseases. A marked difference in bilirubin levels was observed between the groups (p=0.0424) for both genes (Figure 7I).

Discussion

Recent studies have highlighted the potential of lactate and its lactylation modification in cancer progression (59). Lactylation is a post-translational modification of proteins, plays a pivotal role in cellular metabolism, and is increasingly recognized for its involvement in the development of tumors (19, 60). Previous research indicated that the accumulation of lactate in tumors allows the cancer cells to evade the immune system, facilitating their growth and proliferation (61, 62). To elucidate the function of lactylation modification in HCC, we identified common genes between lactylation-related gene set and DEGs as LRGs. These six LRGs (ALB, G6PD, HMGA1, MKI67, RACGAP1, and RFC4) could serve as important markers for HCC. Our bioinformatic investigation indicated a significant association between MKI67 and the RACGAP1 gene in HCC linked to HBV and HCV. Further validation through IHC analysis of patient samples confirmed that these two genes are more strongly correlated with HCC caused by HBV/HCV compared to HCC without viruses. These findings underscore the significance of further investigating the potential of MKI67 and RACGAP1 in predicting outcomes and developing targeted therapies for HCC induced by viruses.

Chronic HBV/HCV infections are prevalent worldwide, with approximately 80% of liver cancer cases (63, 64). HCV is an oncogenic virus that promotes carcinogenesis through cycles of damage and regeneration, driven by molecular mechanisms, including inflammation, proliferation, apoptosis, and genomic alterations (14, 65). Our findings suggest that HCC associated with HCV may exhibit distinct characteristics, particularly in genes linked to lactylation. This emphasizes the importance of identifying specific for predicting disease progression and potential treatment targets, such as viruses-induced HCC.

Recent studies have shown, RACGAP1 expression is correlated with tumor size, clinical grade, histological type, and prognosis in various tumor types. For example, it promotes cell motility and invasion in uterine carcinosarcoma, with its positive expression associated with poorer prognoses (66). Colorectal cancer patients have poor prognoses linked to RACGAP1 expression (67). Another study reported that the overexpression of RACGAP1 also predicts survival rates for squamous cell carcinoma (68). Consistent with these studies, this study also revealed that RACGAP1 is a significant prognostic marker in HCC induced by HBV/HCV via lactylation. These collective findings underscore the importance of RACGAP1 in HCC progression and prognosis.

Previous studies have shown that MKI67 affects immune infiltration and T-cell fatigue and serves as a prognostic biomarker in cancers, especially HCC. Measuring MKI67 levels improves the effectiveness of anti-LIHC immunotherapy by assisting in prognosis prediction (69). Our study also identified the links between clinical indicators, such as increased levels of bilirubin linked to liver dysfunction, and gene activity in patients with HCV (70). Additional comprehensive studies are required to confirm these outcomes and evaluate their clinical applications. This might assist in establishing potentially improving diagnostic and prediction of liver diseases.

The TME plays is pivotal in cancer progression, with lactylation playing a significant role within it (47). In this research, we identified LRGs to predict prognosis in HCC. The results indicated a significant correlation between LRGs and immune cells, demonstrating a positive correlation with, B-cells, Tregs, and Tr1 in LIHC while showing a negative correlation with, macrophages, th17 NK cells, etc. The pathways analysis further supported these findings and underscored the role of immune infiltration in HCC development. These results align with a broader understanding of TME’s role in cancer development and underscore the crucial role of LRGs as biomarkers for immunotherapy strategies in HCC.

Additionally, the correlation with selected ICIs demonstrated a significant correlation between LRGs with ICI markers including, PD-1, PD-L1, and CTLA-4, except for ALB. Moreover, Single-Sample Gene Set Enrichment Analysis (ssGSEA) confirmed that the MKI67 and RACGAP1 are significantly associated with lactylation-related pathways, which are crucial in cancer development (71). Furthermore, the LASSO model identified key lactylation-related prognostic biomarkers for HCC, including MKI67 and RACGAP1 showed a significant predictor while ALB had the least impact. This analysis enhances our understanding of identified LRGs in HCC biology. Collectively, these findings suggest that the LRGs can play a role in immune response therapy strategies, but further studies and clinical trials are needed to assess their efficacy and safety.

Previous studies have reported that identifying biomarkers using genomic analysis significantly improves HCC treatment, yet need to identify more molecules for early diagnosis, and targeted therapies (48). Consistent with these studies, our study shows that LRGs significantly correlated with approved biomarkers like AFP, GPC3, and GP73. Thses results suggest their potential as early diagnostic targets. Further validatory studies are required to confirm these findings and explore the clinical applications.

In summary, we validate our bioinformatics findings by employing IHC analysis of HCC patients’ samples. The current study demonstrated that MKI67 and RACGAP1 are significantly overexpressed in HBV/HCV-related HCC, compared to HCC without viruses. This overexpression suggests a more significant role in the development of HCC induced by HBV/HCV. These results revealed that MKI67 and RACGAP1 can predict outcomes and serve as pivotal therapeutic targets, especially for HCC related to HBV/HCV. This research provides valuable insights into the distinctive features of HCC associated with HBV/HCV and paves the way for new diagnostic and therapeutic strategies.

While this study identified potential biomarkers and therapeutic targets by comprehensive bioinformatics analysis and validation with IHC. However, some limitations can be acknowledged. First, the data was taken from public databases, there may be variations in results due to differences in patient selection and data processing. Secondly, the sample size was limited, which may affect the generalizability of findings. Future prospective cohort studies with a significant number of patients should be conducted. Thirdly our study didn’t consider the several factors that can influence HCC progression including, smoking, alcohol drinking, diabetes, lifestyle, etc. These factors should be considered in future studies for better HCC outcomes. Further studies are needed to investigate the mechanism underlying these interactions and potential therapeutic applications.

Conclusion

In conclusion, this study identified six lactylate-related genes (ALB, G6PD, HMGA1, MKI67, RACGAP1, and RFC4) as promising independent prognostic biomarkers for HCC. MKI67 and RACGAP1 were especially identified as a predictive signature with prognostic potential for HBV and HCV-related HCC. These genes provide insights into poor survival and immune cell infiltration in tumors. Validation using HCC patient samples highlighted that MKI67 and RACGAP1are significantly overexpressed in HBV/HCV positive HCC compared to HCC without viruses. These findings indicate that these genes can work as a potential biomarker for early diagnosis, management, and treatment of HCC caused by HBV/HCV via lactylation.

References

• 1

  HasanMAMManiruzzamanMShinJ. Differentially expressed discriminative genes and significant meta-hub genes based key genes identification for hepatocellular carcinoma using statistical machine learning. Sci Reports. (2023) 13:3771. doi: 10.1038/s41598-023-30851-1

  • CrossRef
  • Google Scholar
  • View reference in article

• 2

  SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalAet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J clinicians. (2021) 71:209–49. doi: 10.3322/caac.21660

  • CrossRef
  • Google Scholar
  • View reference in article

• 3

  CoffinPHeA. Hepatocellular carcinoma: past and present challenges and progress in molecular classification and precision oncology. Int J Mol Sci. (2023) 24(17):13274. doi: 10.3390/ijms241713274

  • CrossRef
  • Google Scholar
  • View reference in article

• 4

  ZhangY-ZZebAChengL-F. Exploring the molecular mechanism of hepatitis virus inducing hepatocellular carcinoma by microarray data and immune infiltrates analysis. Front Immunol. (2022) 13:1032819. doi: 10.3389/fimmu.2022.1032819

  • CrossRef
  • Google Scholar
  • View reference in article

• 5

  SunXWangSLiQ. Comprehensive analysis of expression and prognostic value of sirtuins in ovarian cancer. Front Genet. (2019) 10:879. doi: 10.3389/fgene.2019.00879

  • CrossRef
  • Google Scholar
  • View reference in article

• 6

  JiaLGaoYHeYHooperJDYangP. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res. (2020) 159:104992. doi: 10.1016/j.phrs.2020.104992

  • CrossRef
  • Google Scholar
  • View reference in article

• 7

  YounossiZMYuMLYilmazYAlswatKAButiMFernandezMICet al. Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™. J viral hepatitis. (2023) 30:335–44. doi: 10.1111/jvh.13800

  • CrossRef
  • Google Scholar
  • View reference in article

• 8

  VitaleASvegliati-BaroniGOrtolaniACuccoMDalla RivaGVGianniniEGet al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA. LI CA database Gut. (2023) 72(1):141–52. doi: 10.1136/gutjnl-2021-324915

  • CrossRef
  • Google Scholar
  • View reference in article

• 9

  Razavi-ShearerDGamkrelidzeIPanCJiaJBergTGrayRet al. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. (2023) 8:879–907. doi: 10.1016/S2468-1253(23)00197-8

  • CrossRef
  • Google Scholar
  • View reference in article

• 10

  BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J clinicians. (2018) 68:394–424. doi: 10.3322/caac.21492

  • CrossRef
  • Google Scholar
  • View reference in article

• 11

  JengWJPapatheodoridisGVLokASF. Hepatitis B. Lancet. (2023) 401:1039–52. doi: 10.1016/S0140-6736(22)01468-4

  • CrossRef
  • Google Scholar
  • View reference in article

• 12

  PietschmannTBrownRJ. Hepatitis C virus. Trends microbiol. (2019) 27:379–80. doi: 10.1016/j.tim.2019.01.001

  • CrossRef
  • Google Scholar
  • View reference in article

• 13

  AxleyPAhmedZRaviSSingalAK. Hepatitis C virus and hepatocellular carcinoma: a narrative review. J Clin Trans hepatol. (2018) 6:79. doi: 10.14218/JCTH.2017.00067

  • CrossRef
  • Google Scholar

• 14

  Heredia-TorresTGRincón-SánchezARLozano-SepúlvedaSAGalan-HuertaKArellanos-SotoDGarcía-HernándezMet al. Unraveling the molecular mechanisms involved in HCV-induced carcinogenesis. Viruses. (2022) 14:2762. doi: 10.3390/v14122762

  • CrossRef
  • Google Scholar

• 15

  RaduPBecchettiCSchroppJSchmidPKünzler-HeulePMertensJet al. Effect of direct acting antiviral drugs on the occurrence and recurrence of intra-and extra-hepatic Malignancies in patients with chronic hepatitis C virus infection. Cancers. (2024) 16:2573. doi: 10.3390/cancers16142573

  • CrossRef
  • Google Scholar
  • View reference in article

• 16

  ParkS-JHahnYS. Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment. Clin Mol Hepatol. (2023) 29:65. doi: 10.3350/cmh.2022.0032

  • CrossRef
  • Google Scholar
  • View reference in article

• 17

  ZouYChenZHanHRuanSJinLZhangYet al. Risk signature related to immunotherapy reaction of hepatocellular carcinoma based on the immune-related genes associated with CD8+ T cell infiltration. Front Mol Biosci. (2021) 8:602227. doi: 10.3389/fmolb.2021.602227

  • CrossRef
  • Google Scholar
  • View reference in article

• 18

  ThomasMBJaffeDChotiMMBelghitiJCurleySFongYet al. Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol. (2010) 28:3994–4005. doi: 10.1200/JCO.2010.28.7805

  • CrossRef
  • Google Scholar
  • View reference in article

• 19

  ZhangDTangZHuangHZhouGCuiCWengYet al. Metabolic regulation of gene expression by histone lactylation. Nature. (2019) 574:575–80. doi: 10.1038/s41586-019-1678-1

  • CrossRef
  • Google Scholar

• 20

  LibertiMVLocasaleJW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. (2016) 41(3):211–8. doi: 10.1016/j.tibs.2015.12.001

  • CrossRef
  • Google Scholar

• 21

  HanahanD. Hallmarks of cancer: new dimensions. Cancer discovery. (2022) 12:31–46. doi: 10.1158/2159-8290.CD-21-1059

  • CrossRef
  • Google Scholar

• 22

  GuzmanGChennuriRChanAReaBQuintanaAPatelRet al. Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Digestive Dis Sci. (2015) 60:420–6. doi: 10.1007/s10620-014-3364-3

  • CrossRef
  • Google Scholar

• 23

  ChengZHuangHLiMLiangXTanYChenY. Lactylation-related gene signature effectively predicts prognosis and treatment responsiveness in hepatocellular carcinoma. Pharmaceuticals (Basel). (2023) 16(5):644. doi: 10.3390/ph16050644

  • CrossRef
  • Google Scholar

• 24

  LiMLiHZhouCLiXGongJChenCet al. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of hepatocellular carcinoma (HCC). Med (Baltimore). (2021) 100:e27332. doi: 10.1097/MD.0000000000027332

  • CrossRef
  • Google Scholar

• 25

  WangJHanKZhangCChenXLiYZhuLet al. Identification and validation of ferroptosis-associated gene-based on immune score as prognosis markers for hepatocellular carcinoma patients. J Gastrointestinal Oncol. (2021) 12:2345–60. doi: 10.21037/jgo-21-237

  • CrossRef
  • Google Scholar

• 26

  MenonSSGuruvayoorappanCSakthivelKMRasmiRR. Ki-67 protein as a tumour proliferation marker. Clinica Chimica Acta. (2019) 491:39–45. doi: 10.1016/j.cca.2019.01.011

  • CrossRef
  • Google Scholar

• 27

  StamatiouKHuguetFSerapinasLVSpanosCRappsilberJVagnarelliP. Ki-67 is necessary during DNA replication for fork protection and genome stability. Genome Biol. (2024) 25:105. doi: 10.1186/s13059-024-03243-5

  • CrossRef
  • Google Scholar

• 28

  YangCKYuTDHanCYQinWLiaoXWYuLet al. Genome-wide association study of MKI67 expression and its clinical implications in HBV-related hepatocellular carcinoma in southern China. Cell Physiol Biochem. (2017) 42:1342–57. doi: 10.1159/000478963

  • CrossRef
  • Google Scholar

• 29

  YanPPangPHuXWangAZhangHMaYet al. Specific MiRNAs in naïve T cells associated with hepatitis C virus-induced hepatocellular carcinoma. J Cancer. (2021) 12:1. doi: 10.7150/jca.49594

  • CrossRef
  • Google Scholar

• 30

  EidRASoltanMAEldeenMAShatiAADawoodSAEissaMet al. Assessment of RACGAP1 as a prognostic and immunological biomarker in multiple human tumors: A multiomics analysis. Int J Mol Sci. (2022) 23:14102. doi: 10.3390/ijms232214102

  • CrossRef
  • Google Scholar

• 31

  LaiWSuYLiYZuoYHeKZhangTet al. Elevated RACGAP1 expression enhances Malignant potential in lung adenocarcinoma and serves as a prognostic factor. J Cancer. (2024) 15:4244–58. doi: 10.7150/jca.96334

  • CrossRef
  • Google Scholar

• 32

  ImaokaHToiyamaYSaigusaSKawamuraMKawamotoAOkugawaYet al. RacGAP1 expression, increasing tumor Malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. (2015) 36:346–54. doi: 10.1093/carcin/bgu327

  • CrossRef
  • Google Scholar

• 33

  WuXXuZLiWLuYPuJ. HIF−1α and RACGAP1 promote the progression of hepatocellular carcinoma in a mutually regulatory way. Mol Med Rep. (2023) 28(5):218. doi: 10.3892/mmr.2023.13105

  • CrossRef
  • Google Scholar

• 34

  ChenYShenCWuJYanXHuangQ. Role of immune related genes in predicting prognosis and immune response in patients with hepatocellular carcinoma. J Biochem Mol Toxicol. (2023) 38(1):e23519. doi: 10.1002/jbt.23519

  • CrossRef
  • Google Scholar

• 35

  PengXShiYZhangBXuCLangJ. Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma. J Med Virol. (2023) 95:e29084. doi: 10.1002/jmv.29084

  • CrossRef
  • Google Scholar

• 36

  WangDZhangLSunZJiangHZhangJ. A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma. Eur J Radiol. (2023) 167:111086. doi: 10.1016/j.ejrad.2023.111086

  • CrossRef
  • Google Scholar

• 37

  RoesslerSJiaHLBudhuAForguesMYeQHLeeJSet al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. (2010) 70:10202–12. doi: 10.1158/0008-5472.CAN-10-2607

  • CrossRef
  • Google Scholar

• 38

  SonJAAhnHRYouDBaekGOYoonMGYoonJHet al. Novel gene signatures as prognostic biomarkers for predicting the recurrence of hepatocellular carcinoma. Cancers (Basel). (2022) 14(4):865. doi: 10.3390/cancers14040865

  • CrossRef
  • Google Scholar

• 39

  SungWKZhengHLiSChenRLiuXLiYet al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. (2012) 44:765–9. doi: 10.1038/ng.2295

  • CrossRef
  • Google Scholar

• 40

  Al MarzanAShahiSArmanMSHasanMZGhoshA. A computational approach for investigating biological network of concurrent carcinomas and Type-2 diabetes for screening potential biomarkers. Adv Biomarker Sci Technol. (2023) 5:89–104. doi: 10.1016/j.abst.2023.10.001

  • CrossRef
  • Google Scholar

• 41

  GaoCHYuGCaiP. ggVennDiagram: an intuitive, easy-to-use, and highly customizable R package to generate venn diagram. Front Genet. (2021) 12:706907. doi: 10.3389/fgene.2021.706907

  • CrossRef
  • Google Scholar

• 42

  ItoKMurphyD. Application of ggplot2 to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol. (2013) 2:e79. doi: 10.1038/psp.2013.56

  • CrossRef
  • Google Scholar

• 43

  CsardiGNepuszT. The igraph software. Complex Syst. (2006) 1695:1–9. doi: 10.5281/zenodo.7682609

  • CrossRef
  • Google Scholar

• 44

  WangSSongZTanBZhangJZhangJLiuS. Identification and validation of hub genes associated with hepatocellular carcinoma via integrated bioinformatics analysis. Front oncol. (2021) 11:614531. doi: 10.3389/fonc.2021.614531

  • CrossRef
  • Google Scholar

• 45

  ZhaiYLiuXHuangZZhangJStalinATanYet al. Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma. Sci Rep. (2023) 13:1373. doi: 10.1038/s41598-023-28234-7

  • CrossRef
  • Google Scholar

• 46

  LiXGaoYXuZZhangZZhengYQiF. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods. Cancer Med. (2020) 9:1161–72. doi: 10.1002/cam4.2774

  • CrossRef
  • Google Scholar

• 47

  WuQLiXLongMXieXLiuQ. Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma. Sci Reports. (2023) 13:18642. doi: 10.1038/s41598-023-46057-4

  • CrossRef
  • Google Scholar

• 48

  ChanY-TZhangCWuJLuPXuLYuanHet al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. (2024) 23:189. doi: 10.1186/s12943-024-02101-z

  • CrossRef
  • Google Scholar

• 49

  ChandrashekarDSBashelBBalasubramanyaSAHCreightonCJPonce-RodriguezIChakravarthiBVSKet al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. (2017) 19:649–58. doi: 10.1016/j.neo.2017.05.002

  • CrossRef
  • Google Scholar

• 50

  TangZLiCKangBGaoGLiCZhangZ. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. (2017) 45:W98–W102. doi: 10.1093/nar/gkx247

  • CrossRef
  • Google Scholar

• 51

  GuYLiXBiYZhengYWangJLiXet al. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY). (2020) 12:784–807. doi: 10.18632/aging.102656

  • CrossRef
  • Google Scholar

• 52

  LánczkyANagyÁBottaiGMunkácsyGSzabóASantarpiaLet al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. (2016) 160:439–46. doi: 10.1007/s10549-016-4013-7

  • CrossRef
  • Google Scholar

• 53

  YeYXiangYOzgucFMKimYLiuCJParkPKet al. The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst. (2018) 6:314–28.e2. doi: 10.1016/j.cels.2018.01.013

  • CrossRef
  • Google Scholar

• 54

  LiTFanJWangBTraughNChenQLiuJSet al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. (2017) 77:e108–e10. doi: 10.1158/0008-5472.CAN-17-0307

  • CrossRef
  • Google Scholar

• 55

  CannonMStevensonJStahlKBasuRCoffmanAKiwalaSet al. DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms. Nucleic Acids Res. (2024) 52(D1):D1227–d35. doi: 10.1093/nar/gkad1040

  • CrossRef
  • Google Scholar

• 56

  LiuC-JHuF-FXieG-YMiaoY-RLiX-WZengYet al. GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Briefings Bioinf. (2023) 24:bbac558. doi: 10.1093/bib/bbac558

  • CrossRef
  • Google Scholar

• 57

  VougiouklakisTBelovaracBJLytleAChiribogaLOzerdemU. The diagnostic utility of EZH2 H-score and Ki-67 index in non-invasive breast apocrine lesions. Pathol - Res Practice. (2020) 216:153041. doi: 10.1016/j.prp.2020.153041

  • CrossRef
  • Google Scholar

• 58

  FangLGongJWangYLiuRLiZWangZet al. MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma. J Exp Clin Cancer Res. (2014) 33:76. doi: 10.1186/s13046-014-0076-7

  • CrossRef
  • Google Scholar

• 59

  PengTSunFYangJCCaiMHHuaiMXPanJXet al. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma. World J Gastroenterol. (2024) 30:2575–602. doi: 10.3748/wjg.v30.i19.2575

  • CrossRef
  • Google Scholar

• 60

  GongHZhongHChengLLiLPZhangDK. Post-translational protein lactylation modification in health and diseases: a double-edged sword. J Transl Med. (2024) 22:41. doi: 10.1186/s12967-023-04842-9

  • CrossRef
  • Google Scholar

• 61

  GaoYZhouHLiuGWuJYuanYShangA. Tumor microenvironment: lactic acid promotes tumor development. J Immunol Res. (2022) 2022:3119375. doi: 10.1155/2022/3119375

  • CrossRef
  • Google Scholar

• 62

  YangZYanCMaJPengPRenXCaiSet al. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. Nat Metab. (2023) 5:61–79. doi: 10.1038/s42255-022-00710-w

  • CrossRef
  • Google Scholar

• 63

  WardJWHinmanAR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats. Gastroenterology. (2019) 156:297–310. doi: 10.1053/j.gastro.2018.10.048

  • CrossRef
  • Google Scholar

• 64

  HsuYCHuangDQNguyenMH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. (2023) 20:524–37. doi: 10.1038/s41575-023-00760-9

  • CrossRef
  • Google Scholar

• 65

  IrshadMGuptaPIrshadK. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J Hepatol. (2017) 9:1305–14. doi: 10.4254/wjh.v9.i36.1305

  • CrossRef
  • Google Scholar

• 66

  MiSLinMBrouwer-VisserJHeimJSmotkinDHebertTet al. RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma. Clin Cancer Res. (2016) 22:4676–86. doi: 10.1158/1078-0432.CCR-15-2116

  • CrossRef
  • Google Scholar

• 67

  WangCWangWLiuYYongMYangYZhouH. Rac GTPase activating protein 1 promotes oncogenic progression of epithelial ovarian cancer. Cancer Sci. (2018) 109:84–93. doi: 10.1111/cas.2018.109.issue-1

  • CrossRef
  • Google Scholar

• 68

  Hazar-RethinamMde LongLMGannonOMBorosSVargasACDzienisMet al. RacGAP1 is a novel downstream effector of E2F7-dependent resistance to doxorubicin and is prognostic for overall survival in squamous cell carcinoma. Mol Cancer Ther. (2015) 14:1939–50. doi: 10.1158/1535-7163.MCT-15-0076

  • CrossRef
  • Google Scholar

• 69

  WuS-yLiaoPYanL-yZhaoQ-yXieZ-yDongJet al. Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma. BMC Gastroenterol. (2021) 21:416. doi: 10.1186/s12876-021-01984-2

  • CrossRef
  • Google Scholar

• 70

  Guerra RuizARCrespoJLópez MartínezRMIruzubietaPCasals MercadalGLalana GarcésMet al. Measurement and clinical usefulness of bilirubin in liver disease. Adv Lab Med. (2021) 2(3):352–72. doi: 10.1515/almed-2021-0047

  • CrossRef
  • Google Scholar

• 71

  YuDZhongQWangYYinCBaiMZhuJet al. Lactylation: The metabolic accomplice shaping cancer’s response to radiotherapy and immunotherapy. Ageing Res Rev. (2025) 104:102670. doi: 10.1016/j.arr.2025.102670

  • CrossRef
  • Google Scholar